iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U / mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.15074 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Xiaohui Guo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To evaluate the efficacy of iGlarLixi in the Asian Pacific (AP) population with type 2 diabetes (T2D) using derived time‐in‐ranges calculated from seven‐point self‐measured blood glucose.
Methods
Two phase III trials were analysed. LixiLan‐O‐AP was performed in insulin‐naive T2D patients (n = 878) randomized to iGlarLixi, glargine 100 units/mL (iGlar) or lixisenatide (Lixi). LixiLan‐L‐CN was performed in insulin‐treated T2D patients (n = 426) randomized to iGlarLixi or iGlar. Changes in derived time‐in‐ranges from baseline to end‐of‐treatment (EOT) and estimated treatment differences (ETDs) were analysed. The proportions of patients achieving 70% or higher derived time‐in‐range (dTIR), 5% or higher dTIR improvement, and the composite triple target (≥ 70% dTIR, < 4% derived time‐below‐the‐range [dTBR] and < 25% derived time‐above‐the‐range [dTAR]) were calculated.
Results
The changes from baseline to EOT in dTIR with iGlarLixi were greater versus iGlar (ETD 1 : 11.45% [95% CI, 7.66% to 15.24%]) or Lixi (ETD 2 : 20.54% [95% CI, 15.74% to 25.33%]) in LixiLan‐O‐AP, and versus iGlar (ETD: 16.59% [95% CI, 12.09% to 21.08%]) in LixiLan‐L‐CN. In LixiLan‐O‐AP, the proportions of patients achieving 70% or higher dTIR or 5% or higher dTIR improvement at EOT with iGlarLixi were 77.5% and 77.8%, respectively, higher than with iGlar (61.1% and 75.3%) or Lixi (47.0% and 53.0%). In LixiLan‐L‐CN, the proportions of patients achieving 70% or higher dTIR or 5% or higher dTIR improvement at EOT were 71.4% and 59.8% with iGlarLixi, greater than with iGlar (45.4% and 39.5%). More patients achieved the triple target with iGlarLixi compared with iGlar or Lixi. Conclusion iGlarLixi achieved greater improvements in dTIR parameters versus iGlar or Lixi in insulin‐naïve and insulin‐experienced AP people with T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University First Hospital, Beijing, China.
- China-Japan Friendship Hospital, Beijing, China.
- Jinan Central Hospital, Jinan, China.
- Tianjin Medical University General Hospital, Tianjin, China.
- Sanofi, Shanghai, China.
- Sanofi, Paris, France.
ORCID-Profile: Wenying Yang, Ming Liu
Zitieren
APA
Guo, X., Yang, W., Zhang, J., Dong, X., Liu, M., Gu, S., Lauand, F., Li, L., Huang, Q., Kang, L., & Souhami, E. (2023). iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U / mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15074
Vancouver
Guo X, Yang W, Zhang J, Dong X, Liu M, Gu S, et al. iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U / mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15074
BibTeX
@article{Guo2023,
author = {Guo, Xiaohui and Yang, Wenying and Zhang, Junqing and Dong, Xiaolin and Liu, Ming and Gu, Shenghong and Lauand, Felipe and Li, Lingyu and Huang, Qiong and Kang, Lei and Souhami, Elisabeth},
title = {iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U / mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.15074}
}
EUVIMED